- 
Chinese (Simplified)
 - 
zh-CN
English
 - 
en
French
 - 
fr
German
 - 
de
Hindi
 - 
hi
Russian
 - 
ru
Spanish
 - 
es
Vietnamese
 - 
vi
Next-generation sequencing (NGS) assay that enables in-house comprehensive genomic profiling of tumor samples

Artemis DNA™
RemedySelect Cancer Tumor Profile

Recommended for individuals with cancer in order to determine treatment plan and whether the cancer will come back or spread to other parts of the body. Test is repeated as needed.

Artemis DNA™ RemedySelect Cancer Tumor Profile

Artemis DNA™ RemedySelect Cancer Tumor Profile is a comprehensive next-generation sequencing assay that targets somatic variants, TMB, and MSI status from the same FFPE tumor only sample.

Artemis DNA™ RemedySelect Technology

Artemis DNA™ RemedySelect Cancer Tumor Profile, a next-generation sequencing (NGS) assay that analyzes 523 cancer-relevant genes from both DNA and RNA*. Artemis DNA™ RemedySelect assesses multiple variant types in a single assay, including small nucleotide variants (SNVs), indels, splice variants, fusions, and emerging immunotherapy biomarkers that rely on analysis of multiple genomic loci, such as tumor mutational burden (TMB) and microsatellite instability (MSI).

Artemis DNA™ RemedySelect Cancer Tumor Profile Relevant examples
SNVs and indels KRAS G12D, EGFR exon 19 deletions, BRAF V600E
Fusions ALK, ROS1, NTRK1, NTRK2, NTRK3
Splice variants MET exon 14
MSI MSI-High
TMB TMB-High

The Artemis DNA™ RemedySelect panel includes a comprehensive list of biomarkers commonly mutated in numerous neoplasm types. Artemis DNA™ RemedySelect panel includes 523 genes for SNV and indel detection and 55 genes for fusion and splice variant detection.

Artemis DNA™ RemedySelect Gene List

Artemis DNA™ RemedySelect Frequently Asked Questions

RemedySelect Frequently Asked Questions Section (Coming Soon)

Top